|
Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer Clinical research trials and Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer. Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer clinical trial. Participants oftentimes recieve the finest healthcare available for their Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer  Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer
Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer
For Condition: radiation toxicity,stage 3 squamous cell carcinoma of the oropharynx,stage 2 squamous cell carcinoma of the oropharynx
Status: Recruiting
Sponsor(s): Radiation Therapy Oncology Group , National Cancer Institute (NCI)
Synopsis: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy in treating patients who have stage II or stage III oropharyngeal cancer.
Details: OBJECTIVES: - Assess target coverage and major salivary gland sparing in patients with stage II or III oropharyngeal cancer treated with intensity-modulated radiotherapy. - Determine the nature and prevalence of acute and late side effects of this treatment in these patients. - Determine the rate and pattern of locoregional tumor recurrence in these patients after this treatment. OUTLINE: This is a multicenter study. Patients receive 3-D conformal radiotherapy and/or intensity-modulated radiotherapy daily 5 days a week for 6 weeks, in an effort to spare major salivary glands. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. PROJECTED ACCRUAL: Approximately 57-64 patients will be accrued for this study over 27 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically proven stage II or III (T1-T2, N0-N1) squamous cell carcinoma of the oropharynx (tonsil, base of tongue, or palate) - Lymph nodes in both sides of neck at risk of metastatic disease and require radiotherapy - Patients upstaged by imaging to N2 are eligible - Measurable or evaluable disease - Greater than 1 cm in one dimension or with necrotic regions if by CT or MRI scan - Surgery of the primary tumor or lymph nodes limited to incisional or excisional biopsies - No distant metastases PATIENT CHARACTERISTICS: Age: - Over 18 Performance status: - Zubrod 0-1 Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Not specified Renal: - Not specified Other: - No active untreated infection - No other malignancy within the past 5 years except nonmelanoma skin cancer or a carcinoma not of head or neck origin - No concurrent major medical or psychiatric illness that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - More than 3 months since prior chemotherapy - No concurrent chemotherapy Endocrine therapy: - Not specified Radiotherapy: - No prior head or neck radiotherapy Surgery: - See Disease Characteristics Other: - No other concurrent treatment for head and neck cancer - No prophylactic amifostine or pilocarpine
Total Enrollment:
Location and Contact Information:
Overall Study Official:
AvrahamEisbruch, Study Chair, University of Michigan Comprehensive Cancer Center
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia *Recruiting*
Philadelphia, Pennsylvania, 19107-5541
United States
Recruiting Walter Curran 215-955-6700
University of Texas - MD Anderson Cancer Center *Recruiting*
Houston, Texas, 77030-4009
United States
Recruiting Adam Garden 713-563-2321
UCSF Comprehensive Cancer Center *Recruiting*
San Francisco, California, 94115
United States
Recruiting Janice Ryu 916-734-8251
Centre Hospitalier de l'Universite de Montreal *Recruiting*
Montreal, Quebec, H2L 4MI
Canada
Recruiting Jean-Paul Bahary 514-890-8254
LDS Hospital *Recruiting*
Salt Lake City, Utah, 84143
United States
Recruiting William Sause 801-408-1146
University of Alberta *Recruiting*
Edmonton, Alberta, T6G 2R7
Canada
Recruiting Contact Person 403-492-3111
McGill University *Recruiting*
Montreal, Quebec, H2W 1S6
Canada
Recruiting Luis Souhami 514-934-8040 ext. 43163
Dixie Regional Medical Center *Recruiting*
St. George, Utah, 84770
United States
Recruiting Ray Richards 801-688-4175
Shands Cancer Center at the University of Florida Health Science Center *Recruiting*
Gainesville, Florida, 32610-0385
United States
Recruiting William Mendenhall 352-265-0287
Monmouth Medical Center *Recruiting*
Long Branch, New Jersey, 07740-6395
United States
Recruiting Smitha Gollamudi 732-923-6890
Green Mountain Oncology Group *Recruiting*
Bennington, Vermont, 05201
United States
Recruiting Richard Lovett 802-442-1290
Medical College of Wisconsin Cancer Center *Recruiting*
Milwaukee, Wisconsin, 53226
United States
Recruiting Elizabeth Gore 414-805-4465
All Saints Cancer Center at All Saints Healthcare *Recruiting*
Racine, Wisconsin, 53405
United States
Recruiting James Taylor 262-687-5000
Foundation for Cancer Research and Education *Recruiting*
Phoenix, Arizona, 85013
United States
Recruiting David Brachman 602-274-4484
University of Michigan Comprehensive Cancer Center *Recruiting*
Ann Arbor, Michigan, 48109-0010
United States
Recruiting Howard Sandler 734-936-9338
CCOP - Marshfield Clinic Research Foundation *Recruiting*
Marshfield, Wisconsin, 54449
United States
Recruiting Tarit Banerjee 715-387-5134
Community Medical Center *Recruiting*
Toms River, New Jersey, 08755
United States
Recruiting Bong Chang 732-557-8148
CCOP - Kansas City *Recruiting*
Kansas City, Missouri, 64131
United States
Recruiting Jorge Paradelo 816-823-0555
Additional Information:
Study ID Numbers: CDR0000068231; RTOG-DEV-1065,RTOG-H-0022
Study Start Date:
Record last reviewed: June 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006360
Other Stage 3 Squamous Cell Carcinoma Of The Oropharynx Studies:
1. Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer
2. Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx
3. Chemotherapy With or Without Docetaxel Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
4. Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer
5. High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer
Related Studies:
Other stage 3 squamous cell carcinoma of the oropharynx Clinical Trials
Other Quebec Clinical Trials
Other Montreal Clinical Trials
Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer
|
|
|
|
|
|
|
|
